Clinical Trial Update: Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating perioperative pembrolizumab plus lenvatinib for resectable hepatocellular carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: University College, London | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING